Skip to content

Coulter Partners Top hires for VC & PE portfolio companies Q1-2024

Source: Top global hires bulletin
Share
Copied link to clipboard!

Search Highlights

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

This quarter’s successful placements include:

Function

Focus area

Location

CEO

Therapeutic devices

Austria

Chief Business Officer

Precision biologics

US

Chief Financial Officer

Remote monitoring

France

Chief Strategy Officer

Medical devices

Israel

Chief Medical Officer

Radiopharmaceuticals

US

Chief of Staff

Vaccines

Denmark

VP Global Program Leader, Respiratory

Multi-modality biotech

UK

VP Technology & Product Development

DNA technology

UK

Controller

Contract manufacturing

US

Senior Director Pharmaceutical Development

Drug delivery

Ireland

Director Market Access & Pricing Global

Ophthalmology

Italy

Investment Manager Digital Health

Life sciences investor

Netherlands

General Manager Infectious Diseases

Biocluster

France

Board Director

Personalized digital health

Switzerland

Board Director

Electronic medical instrumentation

US

Board Director

Immunotherapies

Sweden

 

Newly opened projects include:

Function

Focus area

Location

CEO

Medical devices

Belgium

CEO

Precision medicines

US

Chief Commercial Officer

Contract research organization (CRO)

UK

Chief Development Officer

Protein degradation

DACH

Chief Scientific Officer

Small molecules

Spain

Chief Financial Officer

Gene therapy

US

Chief Operating Officer

Incubator/ tech transfer

UK

Head of Strategy & Commercial Excellence

Drug delivery systems

Germany

SVP, Head of Business Development

Drug discovery services

Germany

VP of Science

Precision nutrition

UK

VP, Head of Translational Development

Gene editing

Spain

VP Research & Preclinical

Synthetic biology

UK

VP Business Development

tRNA technologies

US

Life Sciences Partner

Life sciences investor

Italy

Board Director

T-cell therapies

US/ Europe